Form 4: Evolent Health CFO Receives 587,500 RSU Grant

Evolent Health's Chief Financial Officer, Mario Ramos, was granted 587,500 restricted stock units as an employment inducement award.

Summary

• Mario Ramos, Chief Financial Officer of Evolent Health, Inc. (EVH), was granted 587,500 shares of Class A Common Stock.
• This grant represents a special one-time restricted stock unit (RSU) award.
• The award was made pursuant to an employment inducement under Rule 303A.08 of the New York Stock Exchange Listing Manual.
• The RSUs vest over three years: 34% on January 2, 2027, 33% on January 2, 2028, and 33% on January 2, 2029.
• Vesting is contingent on Mr. Ramos's continued employment through the respective vesting dates.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates executive retention and alignment of interests, though with minor dilution.

Positives

• The grant serves as an employment inducement award, potentially enhancing the retention of a key executive (CFO).
• Ties a significant portion of the CFO's future compensation to the company's long-term stock performance, aligning his interests with shareholders.

Negatives

• The issuance of 587,500 shares upon vesting will result in minor dilution for existing shareholders.
• Represents a future compensation expense for the company.

Risks

• The vesting of the restricted stock units is contingent on Mr. Ramos's continued employment through the specified vesting dates.

Future Outlook

The grant is structured to incentivize long-term employment and performance, with vesting contingent on continued service through January 2029. This suggests an expectation of the CFO's continued tenure and contribution to the company's future.

Management Comments

• Represents a special one-time restricted stock unit grant to Mr. Ramos, pursuant to an employment inducement award under Rule 303A.08 of the New York Stock Exchange Listing Manual.
• Upon vesting, each unit is converted into one share of Class A Common Stock, contingent on Mr. Ramos's continued employment through the applicable vesting date.

Industry Context

Executive compensation, particularly through equity grants like restricted stock units, is a common practice in the U.S. public company landscape. These awards are designed to attract, retain, and motivate key executives by aligning their financial interests with the long-term performance of the company's stock. The use of Rule 303A.08 indicates this is an inducement award for a new hire or a significant promotion, which is a standard mechanism for such grants outside of regular equity plans.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a form of executive compensation is a widely adopted practice across various industries, including healthcare technology and services, similar to companies like Teladoc Health, Veeva Systems, or Oracle Health (formerly Cerner).
• Inducement awards, such as this grant under NYSE Rule 303A.08, are standard mechanisms used by companies to attract highly sought-after executives, particularly when they are joining from another company and may be forfeiting existing equity.
• The multi-year vesting schedule (3 years) is typical for long-term incentive plans, aiming to ensure executive retention and sustained performance, comparable to practices at peer companies.

Corporate Governance

Related Party Transactions

• The grant of 587,500 restricted stock units to Mario Ramos, the Chief Financial Officer, constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: Minor potential dilution upon vesting of the RSUs; potential benefit from enhanced executive retention and performance alignment.
• Employees: Signals the company's commitment to attracting and retaining top talent, potentially boosting morale.
• Management: The CFO receives a significant long-term incentive, aligning his financial success with the company's stock performance.

Next Steps

• Vesting of 34% of RSUs on January 2, 2027.
• Vesting of 33% of RSUs on January 2, 2028.
• Vesting of 33% of RSUs on January 2, 2029.

Key Dates

Keywords

Evolent Health, EVH, Mario Ramos, CFO, Restricted Stock Units, RSU, Stock Grant, Executive Compensation, Insider Transaction, Form 4, NYSE Rule 303A.08